Literature DB >> 22555372

Prostanoid EP1 receptor as the target of (-)-epigallocatechin-3-gallate in suppressing hepatocellular carcinoma cells in vitro.

Juan Jin1, Yan Chang, Wei Wei, Yi-fu He, Shan-shan Hu, Di Wang, Yu-jing Wu.   

Abstract

AIM: To investigate the effects of (-)-epigallocatechin-3-gallate (EGCG), an active compound in green tea, on prostaglandin E(2) (PGE(2))-induced proliferation and migration, and the expression of prostanoid EP(1) receptors in hepatocellular carcinoma (HCC) cells.
METHODS: HCC cell line HepG2, human hepatoma cell lines MHCC-97L, MHCC-97H and human hepatocyte cell line L02 were used. Cell viability was analyzed using MTT assay. PGE(2) production was determined with immunoassay. Wound healing assay and transwell filter assay were employed to assess the extent of HCC cell migration. The expression of EP(1) receptor and Gq protein were examined using Western blot assay.
RESULTS: PGE(2) (4-40000 nmol/L) or the EP(1) receptor agonist ONO-DI-004 (400-4000 nmol/L) increased the viability and migration of HepG2 cells in concentration-dependent manners. EGCG (100 μg/mL) significantly inhibited the viability and migration of HepG2 cells induced by PGE(2) or ONO-DI-004. HepG2 cells secreted an abundant amount of PGE(2) into the medium, and EGCG (100 μg/mL) significantly inhibited the PGE(2)production and EP(1) receptor expression in HepG2 cells. EGCG (100 μg/mL) also inhibited the viability of MHCC-97L cells, but not that of MHCC-97H cells. Both EGCG (100 μg/mL) and EP(1) receptor antagonist ONO-8711 inhibited PGE(2) 4 μmol/L and ONO-DI-004 400 nmol/L-induced growth and migration of HepG2 cells. Both EGCG (100 μg/mL) and ONO-8711 210 nmol/L inhibited PGE(2)- and ONO-DI-004-induced EP(1) expression. EGCG and ONO-8711 had synergistic effects in inhibiting EP(1) receptor expression. PGE(2), ONO-DI-004, ONO-8711, and EGCG had no effects on Gq expression in HepG2 cells, respectively.
CONCLUSION: These findings suggest that the anti-HCC effects of EGCG might be mediated, at least partially, through the suppressing EP(1) receptor expression and PGE(2) production.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22555372      PMCID: PMC4010354          DOI: 10.1038/aps.2012.13

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  27 in total

1.  Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice.

Authors:  C H Liu; S H Chang; K Narko; O C Trifan; M T Wu; E Smith; C Haudenschild; T F Lane; T Hla
Journal:  J Biol Chem       Date:  2001-03-07       Impact factor: 5.157

2.  (-)-Epigallocatechin 3-gallate (EGCG) at the ocular surface inhibits corneal neovascularization.

Authors:  V Sánchez-Huerta; L Gutiérrez-Sánchez; J Flores-Estrada
Journal:  Med Hypotheses       Date:  2010-10-23       Impact factor: 1.538

3.  Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development.

Authors:  T Kawamori; N Uchiya; S Nakatsugi; K Watanabe; S Ohuchida; H Yamamoto; T Maruyama; K Kondo; T Sugimura; K Wakabayashi
Journal:  Carcinogenesis       Date:  2001-12       Impact factor: 4.944

4.  Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1 beta-induced activity and expression of cyclooxygenase-2 and nitric oxide synthase-2 in human chondrocytes.

Authors:  Salahuddin Ahmed; Ayesha Rahman; Absarul Hasnain; Matthew Lalonde; Victor M Goldberg; Tariq M Haqqi
Journal:  Free Radic Biol Med       Date:  2002-10-15       Impact factor: 7.376

Review 5.  Antioxidant activity of tea polyphenols in vivo: evidence from animal studies.

Authors:  Balz Frei; Jane V Higdon
Journal:  J Nutr       Date:  2003-10       Impact factor: 4.798

6.  Topical applications of caffeine or (-)-epigallocatechin gallate (EGCG) inhibit carcinogenesis and selectively increase apoptosis in UVB-induced skin tumors in mice.

Authors:  Yao-Ping Lu; You-Rong Lou; Jian-Guo Xie; Qing-Yun Peng; Jie Liao; Chung S Yang; Mou-Tuan Huang; Allan H Conney
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-30       Impact factor: 11.205

Review 7.  Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer?

Authors:  Mark A Hull; Stanley C W Ko; Gillian Hawcroft
Journal:  Mol Cancer Ther       Date:  2004-08       Impact factor: 6.261

8.  Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis.

Authors:  Jing Leng; Chang Han; A Jake Demetris; George K Michalopoulos; Tong Wu
Journal:  Hepatology       Date:  2003-09       Impact factor: 17.425

9.  Mechanisms of inhibition of tumor angiogenesis and vascular tumor growth by epigallocatechin-3-gallate.

Authors:  Gianfranco Fassina; Roberta Venè; Monica Morini; Simona Minghelli; Roberto Benelli; Douglas M Noonan; Adriana Albini
Journal:  Clin Cancer Res       Date:  2004-07-15       Impact factor: 12.531

10.  Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats.

Authors:  S Nakatsugi; T Ohta; T Kawamori; M Mutoh; T Tanigawa; K Watanabe; S Sugie; T Sugimura; K Wakabayashi
Journal:  Jpn J Cancer Res       Date:  2000-09
View more
  11 in total

1.  Green tea component epigallocatechin-3-gallate decreases expression of osteopontin via a decrease in mRNA half-life in cell lines of metastatic hepatocellular carcinoma.

Authors:  Matthew A C Zapf; Anai N Kothari; Cynthia E Weber; Matthew L Arffa; Phillip Y Wai; Joseph Driver; Gopal N Gupta; Paul C Kuo; Zhiyong Mi
Journal:  Surgery       Date:  2015-07-17       Impact factor: 3.982

Review 2.  Multifaceted roles of PGE2 in inflammation and cancer.

Authors:  Masako Nakanishi; Daniel W Rosenberg
Journal:  Semin Immunopathol       Date:  2012-09-21       Impact factor: 9.623

Review 3.  Emerging targets in lipid-based therapy.

Authors:  Stephanie C Tucker; Kenneth V Honn
Journal:  Biochem Pharmacol       Date:  2012-12-20       Impact factor: 5.858

4.  Cyclooxygenase-2 expression is associated with initiation of hepatocellular carcinoma, while prostaglandin receptor-1 expression predicts survival.

Authors:  Hao-Jie Yang; Jing-Hang Jiang; Yu-Ting Yang; Xiang-Di Yang; Zhe Guo; Ya-Peng Qi; Feng-Hua Zeng; Ke-Lan Zhang; Neng-Zhi Chen; Bang-De Xiang; Le-Qun Li
Journal:  World J Gastroenterol       Date:  2016-10-21       Impact factor: 5.742

Review 5.  Novel Investigations of Flavonoids as Chemopreventive Agents for Hepatocellular Carcinoma.

Authors:  Chen-Yi Liao; Ching-Chang Lee; Chi-chang Tsai; Chao-Wen Hsueh; Chih-Chiang Wang; I-Hung Chen; Ming-Kai Tsai; Mei-Yu Liu; An-Tie Hsieh; Kuan-Jen Su; Hau-Ming Wu; Shih-Chung Huang; Yi-Chen Wang; Chien-Yao Wang; Shu-Fang Huang; Yen-Cheng Yeh; Ren-Jy Ben; Shang-Tao Chien; Chin-Wen Hsu; Wu-Hsien Kuo
Journal:  Biomed Res Int       Date:  2015-12-16       Impact factor: 3.411

6.  A new molecular mechanism underlying the EGCG-mediated autophagic modulation of AFP in HepG2 cells.

Authors:  Lin Zhao; Shengtang Liu; Jiaying Xu; Wei Li; Guangxin Duan; Haichao Wang; Huilin Yang; Zaixing Yang; Ruhong Zhou
Journal:  Cell Death Dis       Date:  2017-11-02       Impact factor: 8.469

7.  Antitumoral effect of Ocoxin in hepatocellular carcinoma.

Authors:  Elena Díaz-Rodríguez; Al-Mahy El-Mallah; Eduardo Sanz; Atanasio Pandiella
Journal:  Oncol Lett       Date:  2017-06-21       Impact factor: 2.967

Review 8.  Emerging Roles of G Protein-Coupled Receptors in Hepatocellular Carcinoma.

Authors:  Wen-Ting Peng; Wu-Yi Sun; Xin-Ran Li; Jia-Chang Sun; Jia-Jia Du; Wei Wei
Journal:  Int J Mol Sci       Date:  2018-05-04       Impact factor: 5.923

9.  Prostaglandin E1 protects hepatocytes against endoplasmic reticulum stress-induced apoptosis via protein kinase A-dependent induction of glucose-regulated protein 78 expression.

Authors:  Fang-Wan Yang; Yu Fu; Ying Li; Yi-Huai He; Mao-Yuan Mu; Qi-Chuan Liu; Jun Long; Shi-De Lin
Journal:  World J Gastroenterol       Date:  2017-10-28       Impact factor: 5.742

Review 10.  Epigallocatechin-3-gallate in the prevention and treatment of hepatocellular carcinoma: experimental findings and translational perspectives.

Authors:  Sabrina Bimonte; Vittorio Albino; Mauro Piccirillo; Aurelio Nasto; Carlo Molino; Raffaele Palaia; Marco Cascella
Journal:  Drug Des Devel Ther       Date:  2019-02-12       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.